Chest
Clinical InvestigationsCOPDA Comparison of the Effects of Salbutamol and Ipratropium Bromide on Exercise Endurance in Patients With COPDa
Section snippets
Patients
We recruited a total of 67 consecutive patients with clinically stable COPD, as defined by the American Thoracic Society,10between January 1999 and December 2001. The entry criteria for the study included the following: (1) age > 50 years; (2) a history of cigarette smoking of > 20 pack-years; (3) FEV1 of < 80% of the predicted value; and (4) best postbronchodilator FEV1/FVC ratio of < 0.7. The present study included those who had mild-to-severe airflow limitation. The exclusion criteria
Results
The baseline characteristics of the 67 COPD patients are presented in Table 1. Their mean age was 70.4 ± 5.6 years, and the mean FEV1 was 1.15 ± 0.41 L (44.2 ± 15.5% predicted). The effects of salbutamol and ipratropium bromide on pulmonary function and the results of the exercise performance tests are presented in Table 2. At 30 min, both bronchodilators produced significant improvements in FEV1 and FVC compared to placebo (p < 0.001). When comparing the changes between the two
Discussion
We found that salbutamol and ipratropium bromide had significant and similar effects on exercise capacity in stable patients with COPD, using the endurance time as an index of exercise capacity. In addition, the response to the different bronchodilators was shown to vary within individuals, for both FEV1 and exercise capacity.
We demonstrated that the endurance time after therapy with salbutamol and ipratropium bromide were similar in 67 patients with COPD. Previous studies have addressed the
References (23)
- et al.
Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone
Chest
(1995) - et al.
A comparison of the bronchodilating effects of oxitropium bromide and fenoterol in patients with chronic obstructive pulmonary disease
Chest
(1993) Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD
Chest
(1991)- et al.
The effect of inhaled terbutaline on FEV1, FVC, dyspnoea and walking distance in patients with chronic obstructive lung disease
Respir Med
(1992) - et al.
Is an anticholinergic agent superior to a β2-agonist in improving dyspnea and exercise limitation in COPD?
Chest
(1995) - et al.
A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD
Chest
(2002) - et al.
Combination therapy for asthma and chronic obstructive pulmonary disease
(2000) - et al.
Effect of terbutaline on exercise capacity and pulmonary function in patients with chronic obstructive pulmonary disease
Lung
(1999) - et al.
Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airflow limitation
Thorax
(1994) - et al.
Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease
Thorax
(1996)
The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease: a comparison of three different exercise tests
Am J Respir Crit Care Med
Cited by (38)
A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM
2013, Respiratory MedicineCitation Excerpt :The changes in static and dynamic pulmonary volumes, such as IC and VT, demonstrate a better correlation with exercise outcomes. Therefore, establishing only FEV1 as an outcome to consider the response to BD may underestimate the occurrence of significant clinical benefits [6,14,15,29]. Our results are in the same line with those reported in COPD patients, since increase in FEV1 after salbutamol was not associated with increase in IC, even in the subgroup DH, and there was not a consistent benefit over dynamic hyperinflation.
Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease
2012, Journal of Pain and Symptom ManagementAcute administration of bronchodilators on exercise tolerance in treated COPD patients
2011, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :In addition to their regular pharmacologic treatment, COPD patients are often used to administer extra-doses of short-acting inhaled bronchodilators in presence of symptoms or in anticipation of making an effort. Few clinical trials have been conducted using a single-dose of bronchodilators, mainly salbutamol and/or ipratropium bromide, before performing an endurance test, and they reported conflicting results: some of these demonstrated that acute pre-treatment with bronchodilators determined a longer ET while others reported only an improvement in forced expiratory flow and a reduction in dynamic hyperinflation [10–13]. In these studies, patients withdrew their regular treatment some hours before the study drug administration, and therefore this study design does not represent the real situation experienced by the patients.
The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD
2007, Respiratory MedicineCitation Excerpt :If anything, this is likely to be an under-estimate of the true improvement possible in these patients since the most effective treatment in terms of increased exercise performance was associated with less breathlessness and presumably, a greater capacity to increase exercise further. A composite endpoint of breathlessness per metre walked has been reported in pharmacological trials29,30 and this endpoint also distinguished between patients receiving the different treatments. However, it was no better than reporting only walking distance in our patients.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (e-mail: [email protected]).